芪蛭降糖胶囊联合西格列汀治疗2型糖尿病的临床研究  

Clinical study on Qizhi Jiangtang Capsules combined with sitagliptin in treatment of type 2 diabetes mellitus

作　　者：段俞伽[1] 杨志霞[1] 张鹏[2] 段冬梅 李改仙[3] DUAN Yu-jia;YANG Zhi-xia;ZHANG Peng;DUAN Dong-mei;LI Gai-xian(Department of Endocrinology,the People's Hospital of Langfang City,Langfang 065000,China;Department of Orthopedics,the People's Hospital of Langfang City,Langfang 065000,China;Department of Endocrinology,North China Petroleum General Hospital Affiliated to Hebei Medical University,Cangzhou 062552,China)

机构地区：[1]廊坊市人民医院内分泌科,河北廊坊065000 [2]廊坊市人民医院骨科,河北廊坊065000 [3]河北医科大学附属华北石油总医院内分泌科,河北沧州062552

出　　处：《现代药物与临床》2019年第5期1478-1482,共5页Drugs & Clinic

摘　　要：目的探讨芪蛭降糖胶囊联合西格列汀治疗2型糖尿病的临床效果。方法选取2016年6月—2018年6月廊坊市人民医院收治的2型糖尿病患者126例,随机分成对照组(63例)和治疗组(63例)。对照组口服磷酸西格列汀片,1片/次,1次/d。治疗组在对照组基础上口服芪蛭降糖胶囊,2.5 g/次,3次/d。两组患者均连续治疗12周。观察两组患者临床疗效,同时比较治疗前后两组患者症状积分、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、三酰甘油(TG)/高密度脂蛋白胆固醇(HDL-C)、载脂蛋白(Apo)-CⅢ/Apo-CⅡ比值及胰岛功能相关参数。结果治疗后,对照组和治疗组临床有效率分别为81.0%和93.7%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组患者症状积分均显著降低(P<0.05),且治疗组患者上述症状积分明显低于对照组(P<0.05)。治疗后,两组血浆FPG、HbA1c水平及血清TG/HDL-C、Apo-CⅢ/Apo-CⅡ比值均显著下降(P<0.05),且治疗组患者这些指标水平明显低于对照组(P<0.05)。治疗后,两组患者血浆空腹胰岛素(FINS)、C肽(C-P)、胰高血糖素(GC)浓度和胰岛素抵抗指数(HOMA-IR)值较治疗前均显著下降(P<0.05),胰岛β细胞功能指数(HOMA-β)值均显著升高(P<0.05),且治疗组患者上述胰岛功能相关参数水平明显好于对照组(P<0.05)。结论芪蛭降糖胶囊联合西格列汀治疗2型糖尿病能有效减轻患者症状,平稳控制血糖,调节血脂,改善胰岛功能,降低胰岛素抵抗。Objective To investigate the clinical effects of Qizhi Jiangtang Capsules combined with sitagliptin in treatment of type 2 diabetes mellitus.Methods Patients (126 cases) with type 2 diabetes mellitus in the People's Hospital of Langfang City from June 2016 to June 2018 were randomly divided into control (63 cases) and treatment (63 cases) groups.Patients in the control group were po administered with Sitagliptin Phosphate Tablets,1 tablet/time,once daily.Patients in the treatment group were po administered with Qizhi Jiangtang Capsules on the basis of the control group,2.5 g/time,three times daily.Patients in two groups were treated for 12 weeks.After treatment,the clinical efficacy was evaluated,and the symptom scores,FPG,HbA1c,TG/HDL-C,Apo-CⅢ/Apo-CⅡ,the related parameters of islet function in two groups before and after treatment were compared.Results After treatment,the clinical efficacy and in the control and treatment groups was 81.0% and 93.7% respectively,and there were differences between two groups (P < 0.05).After treatment,the symptom scores in two groups were significantly decreased (P < 0.05),and which in the treatment group were significantly lower than those in the control group (P < 0.05).After treatment,the plasma levels of FPG and HbA1c,TG/HDL-C and Apo-CⅢ/Apo-CⅡ in two groups were significantly decreased (P < 0.05),and these indexes in the treatment group were significantly lower than those in the control group (P < 0.05).After treatment,the plasma concentration of FINS,C-P and GC,and HOMA-IR value in two groups were significantly decreased (P < 0.05),but HOMA-β value was significantly increased (P < 0.05),and the related parameters of islet function in the treatment group were significantly better than those in the control group (P < 0.05).Conclusion Qizhi Jiangtang Capsules combined with sitagliptin in treatment of type 2 diabetes mellitus can effectively alleviate the symptoms,control blood sugar smoothly,regulate blood lipids,improve islet function and reduce insulin resistance.

关 键 词：芪蛭降糖胶囊 磷酸西格列汀片 2型糖尿病 空腹血糖 糖化血红蛋白 胰岛功能 胰岛素抵抗 

分 类 号：R977[医药卫生—药品]